To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

Satellite Symposium Proceedings Movement Disorders Conclusion There is growing acceptance that the needs of patients with spasticity are best addressed by taking a comprehensive approach to their management – i.e. one that encompasses the patient’s physical needs and mental wellbeing, beginning at the first assessment and continuing through the various stages of the rehabilitation process. The use of GAS 1. Houlden H, Charlton P, Singh D, Neurology and orthopaedics, J Neurol Neurosurg Psychiatry, 2007;78:224–32. 2. Turner-Stokes L, Fheodoroff K, Jacinto J, et al., Upper limb international spasticity study: rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice, BMJ Open, 2013;3:e002230. 3. Becker G, Kaufman SR, Managing an uncertain illness trajectory in old age: patients’ and physicians’ views of stroke, Med Anthropol Q, 1995;9:165–87. 4. Pound P, Bury M, Gompertz P, et al., Views of survivors of stroke on benefits of physiotherapy, Qual Health Care, 1994;3:69–74. 5. Turner-Stokes L, Goal attainment scaling (GAS) in rehabilitation: a practical guide, Clin Rehabil, 2009;23:362–70. 6. Turner-Stokes L, Baguley IJ, De Graaff S, et al., Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double- blind placebo-controlled randomized clinical trial, J Rehabil Med, 2010;42:81–9. 7. Doan QV, Brashear A, Gillard PJ, et al., Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity, PMR, 2012;4:4–10. 8. Sturm JW, Donnan GA, Dewey HM, et al., Quality of life after stroke. The North East Melbourne Stroke Incidence Study (NEMESIS), Stroke, 2004;35:2340–5. 9. Kiresuk TJ, Sherman RE, Goal attainment scaling: A general method for evaluating comprehensive community mental health programs, Community Ment Health J, 1968;4:443–53. 10. Wade DT, Goal setting in rehabilitation: an overview of what, why and how, Clin Rehab, 2009;23:291–5. 11. McCrory P, Turner-Stokes L, Baguley IJ, et al., Botulinum toxin A for treatment of upper limb spasticity Following stroke: a multi-centre randomized placebo-controlled Study of the effects on quality of life and other person-centred outcomes, J Rehabil Med, 2009;41:536–44. 12. Turner-Stokes L, Vanderstay R, Stevermuer T, et al., Comparison of rehabilitation outcomes for long term neurological conditions: a cohort analysis of the Australian rehabilitation outcomes centre dataset for adults of working age, PLoS One, 2015;10:e0132275. 13. Barnes M, Fheodoroff K, Kocer S, et al., Information and 40 can engage and motivate patients to play a full part alongside their care teams. Appropriate clinical assessment scales provide meaningful information for the physician in regards to the complete treatment plan, including BoNT-A and a rehabilitation program. Guided self- rehabilitation might help to achieve the best possible outcomes. ■ treatment gaps in the management of spasticity: Results from an international survey. Presented at: IneReM, Istanbul, Turkey, 4–6 June 2015. 14. Turner-Stokes L, Fheodoroff K, Jacinto J, et al., Results from the Upper Limb International Spasticity Study-II (ULISII): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management, BMJ Open, 2013;3:e002771. 15. Scobbie L, Dixon D, Wyke S, Goal setting and action planning in the rehabilitation setting: development of a theoretically informed practice framework, Clin Rehabil, 2011;25:468–82. 16. Fheodoroff K, Ashford S, Jacinto J, et al., Factors influencing goal attainment in patients with post-stroke upper limb spasticity following treatment with botulinum toxin a in real- life clinical practice: sub-analyses from the Upper Limb International Spasticity (ULIS)-II study, Toxins, 2015;7:1192–205. 17. Ashford S, Turner-Stokes L, Upper Limb Spasticity Index. Available at: (accessed 11 January 2015). 18. Bakheit AM, Zakine B, Maisonobe P, et al.,The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey, Int J Rehabil Res, 2010;33:199–204. 19. Bohannon RW, Smith MB, Assessment of strength deficits in eight paretic upper extremity muscle groups of stroke patients with hemiplegia, Phys Ther, 1987;67:522–5. 20. Tardieu G, Rondont O, Mensch J, et al., Responses electromyographiques a l’etirement musculaire chez l’homme normal, Rev Neurol, 1957;97:60–1. 21. Gracies JM, Bayle N, Vinti M, et al., Five step clinical assessment in spastic paresis, Eur J Phys Rehabil Med, 2010;46:411–21. 22. Sunnerhagen KS, Olver J, Francisco GE, Assessing and treating functional impairment in poststroke spasticity, Neurology, 2013;80(3 Suppl. 2):S35–544. 23. Patrick E, Ada L. The Tardieu Scale differentiates contracture from spasticity whereas the Ashworth Scale is confounded by it, Clin Rehabil, 2006;20:173–82. 24. Gracies JM, Marosszeky JE, Renton R, et al., Short-term effects of dynamic Lycra splints on upper limb in hemiplegic patients, Arch Phys Med Rehabil, 2000;81:1547–55. 25. Ashford S, Turner-Stokes L, Goal attainment for spasticity management using botulinum toxin, Physiother Res Int, 2006;11:24–34. 26. Gracies JM, Brashear A, McAllister P, et al., Randomized, double-blind placebo-controlled Phase III study of Dysport, AbobotulinumtoxinA, in the treatment of adults with upper limb spasticity. Poster 404, ISPRM 2014. 27. Gracies JM, Khatkova S, Skoromets A, et al., Spastic movement disorder treated by AbobotulinumtoxinA (Dysport) in the hemiparetic upper limb: a randomized, double-blind, placebo-controlled, Phase III study. Abstract MDS 2014 LBA125. 28. Skilbeck CE, Wade DT, Hewer RL, et al., Recovery after stroke, J Neurol Neurosurg Psychiatry, 1983;46:5–8. 29. Moore JL, Roth EJ, Killian C, et al., Locomotor training improves daily stepping activity and gait efficiency in individuals poststroke who have reached a “plateau” in recovery, Stroke, 2010;41:129–135. 30. Gracies JM, Pathophysiology of spastic paresis. Part I. Paresis and soft tissue contracture, Muscle Nerve 2005;31:535–55. 31. Gracies JM, Pathophysiology of spastic paresis. Part II. The emergence of muscle overactivity. Muscle Nerve 2005;31:552–571. 32. Gracies JM, Coefficients of impairment in deforming spastic paresis, Ann Phys Rehab Med, 2015;58:173–178. 33. Cordo P, Lutsep H, Cordo L, et al., Assisted movement with enhanced sensation (AMES): coupling motor and sensory to remediate motor deficits in chronic stroke patients, Neurorehabil Neural Repair, 2009;23:67–77. 34. Cauraugh JH, Lodha N, Naik SK, et al., Bilateral movement training and stroke motor recovery progress: a structured review and meta-analysis, Hum Mov Sci, 2010;29:853–870. 35. Ada L, Goddard E, McCully J, et al., Thirty minutes of positioning reduces the development of shoulder external rotation contracture after stroke: a randomized controlled trial, Arch Phys Med Rehabil, 2005;86:230-234. 36. Gracies JM, Blondel R, Gault-Colas C, et al., Contrat d’Autorééducation Guidée dans la parésie spastique. De Boeck edition, ©Association Neurorééducation en Mouvement, Paris 2013;108. 37. Gracies JM, Alkandari S, Nicolas Bayle N, et al., Effects of self- rehabilitation contracts combined with repeated botulinum toxin injections on walking speed in chronic hemiparesis. A prospective open-label study. Poster Presentation 0231 INEREM 2015. EUR OP EAN NE U R OL OG ICA L RE VIE W